ScholarIQanswers from OpenAlex & ORCID
Chia‐Yu Chu
ResearcherPublications, citations & collaboration network
Chia‐Yu Chu is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Chia‐Yu Chu have?
ScholarIQindexed works
Chia‐Yu Chu has 383 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Chia‐Yu Chu have?
ScholarIQcitation count
Chia‐Yu Chu has 13,131 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Chia‐Yu Chu?
ScholarIQh-index
Chia‐Yu Chu has an h-index of 52 in OpenAlex.
What is the i10-index of Chia‐Yu Chu?
ScholarIQi10-index
Chia‐Yu Chu has an i10-index of 160 in OpenAlex.
What is the ORCID of Chia‐Yu Chu?
ScholarIQorcid
The ORCID for Chia‐Yu Chu is on the source record.
What is the OpenAlex record for Chia‐Yu Chu?
ScholarIQopenalex
The OpenAlex for Chia‐Yu Chu is on the source record.
What are the most-cited papers on Chia‐Yu Chu?
ScholarIQmost cited works
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Wen‐Hung Chung, Wen‐Hung Chung, Lieh-Bang Liou, C.C. Chu, Marie Lin, Hsien-Ping Huang, Yen-Ling Lin, Joung-Liang Lan, Li-Cheng Yang, Hong-shang Hong, Ming-Jing Chen, Ping-Chin Lai, Mai-Szu Wu, Chia‐Yu Chu, Kuo-Hsien Wang, Chien‐Hsiun Chen, Cathy S.J. Fann, Jer-Yuarn Wu, Yuan-Tsong Chen
Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study
Sylvia H. Kardaun, Peggy Sekula, L. Valeyrie‐Allanore, Y. Liss, Chia‐Yu Chu, D. Creamer, Alexis Sidoroff, Luigi Naldi, Maja Mockenhaupt, J C Roujeau, the RegiSCAR study group
The SCFbeta -TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in Ikappa Balpha and beta -catenin and stimulates Ikappa Balpha ubiquitination in vitro
Jeffrey Winston, Peter R. Strack, Peggy Beer‐Romero, Chia‐Yu Chu, Stephen J. Elledge, J. Wade Harper
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson, Kim Papp, Aileen L. Pangan, Andrew Blauvelt, Diamant Thaçi, Chia‐Yu Chu, Hyuck-Ki Hong, Norito Katoh, Amy S. Paller, Brian Calimlim, Yihua Gu, Xiaofei Hu, Meng Liu, Yang Yang, John Liu, Allan R. Tenorio, Alvina D. Chu, Alan D. Irvine
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Thomas Bieber, Eric L. Simpson, Jonathan I. Silverberg, Diamant Thaçi, C. Paul, Andrew Pink, Yoko Kataoka, Chia‐Yu Chu, Marco DiBonaventura, Ricardo Rojo, Jeremias Antinew, Ileana A. Ionita, Rodney Sinclair, Seth Forman, Jacek Zdybski, Pinaki Biswas, Bimal Malhotra, Fan Zhang, Hernán Valdez